Omalizumab for the treatment of chronic spontaneous urticaria: association between body mass index and outcome
Introduction: Omalizumab has been recently registered as a third-line therapy for chronic spontaneous urticaria. Objectives: In this study, we aimed to provide real life data by reporting our experience with omalizumab in the treatment of chronic spontaneous urticaria. Methods: A retrospective data...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Mattioli1885,
2022-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|